Hence, although we detected the decreased numbers of Tregs, tumor-associated macrophages and tumor-associated neutrophils, and increased numbers of functional DCs, CD4+, and CD8+ T cells on day 3 after RFA treatment, the transient immune responses lacked the ability to suppress tumor growth. The gene discussed is CD8A; the disease is neoplasm.